[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 58 of about 58
1. Hidaka H, Nakamura N, Asano S, Yokoyama J, Yoshida N, Toshima M: A case of lymphoepithelioma-like carcinoma arising from the palatine tonsil. Tohoku J Exp Med; 2002 Oct;198(2):133-40
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of lymphoepithelioma-like carcinoma arising from the palatine tonsil.
  • Lymphoepithelioma is the designation that has been given to describe undifferentiated squamous cell carcinoma variants of nasopharyngeal neoplasms (World Health Organization type 3), and a strong association with Epstein-Barr virus (EBV) infection has been established.
  • Outside the nasopharynx, lymphoepithelioma-like carcinomas (LEC) are exceedingly rare in other head and neck lesions.
  • Diagnosis of lymphoepithelioma was finally made based on the pathological review of the tonsillectomy specimens, preceded by a cervical lymph node biopsy.
  • The patient was treated with irradiation and adjuvant chemotherapy.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Squamous Cell / pathology. Palatine Tonsil. Pharyngeal Neoplasms / pathology
  • [MeSH-minor] DNA, Viral / analysis. Diagnosis, Differential. Herpesvirus 4, Human / genetics. Humans. In Situ Hybridization. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction. RNA, Viral / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12512998.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


2. Chedid HM, Franzi SA, Dedivitis RA: Assessment of clinical and therapeutic factors in patients with nasopharyngeal undifferentiated carcinoma. Braz J Otorhinolaryngol; 2008 Jul-Aug;74(4):566-70
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of clinical and therapeutic factors in patients with nasopharyngeal undifferentiated carcinoma.
  • The nasopharyngeal carcinoma (NPC) is a rare cancer with a high incidence in Southern Asia.
  • AIM: To study the demographic, clinical, therapeutic, and prognostic factors of nasopharyngeal undifferentiated carcinoma in a reference service.
  • The patients had no previous treatment and did not present any evidence of synchronous tumors or distance metastases.
  • Curative treatment consisted of radiotherapy and simultaneous chemotherapy in clinical stages III and IV.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852983.001).
  • [ISSN] 1808-8694
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Benasso M, Sanguineti G, D'Amico M, Corvò R, Ricci I, Numico G, Guarneri D, Vitale V, Pallestrini E, Santelli A, Rosso R: Induction chemotherapy followed by alternating chemo-radiotherapy in stage IV undifferentiated nasopharyngeal carcinoma. Br J Cancer; 2000 Dec;83(11):1437-42
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy followed by alternating chemo-radiotherapy in stage IV undifferentiated nasopharyngeal carcinoma.
  • In locally advanced undifferentiated nasopharyngeal carcinoma (UNPC), concomitant chemo-radiotherapy is the only strategy that gave better results over radiation alone in a phase III trial.
  • Adding effective chemotherapy to a concomitant chemo-radiotherapy programme may be a way to improve the results further.
  • 30 patients with previously untreated T4 and/or N2-3 undifferentiated nasopharyngeal carcinoma were consecutively enrolled and initially treated with 3 courses of epidoxorubicin, 90 mg/m2, day 1 and cisplatin, 40 mg/m2, days 1 and 2, every 3 weeks.
  • After a radiological and clinical response assessment patients underwent 3 courses of cisplatin, 20 mg/m2/day, days 1-4 and fluorouracil, 200 mg/m2/day, days 1-4, i.v. bolus, (weeks 1, 4, 7) alternated to 3 courses of radiation (week 2-3, 5-6, 8-9-10), with a single daily fractionation, up to 70 Gy.
  • WHO histology was type 2 in 30% and type 3 in 70% of the patients.
  • All but one received 3 courses of induction chemotherapy.
  • All the patients but one had the planned number of chemotherapy courses in the alternating phase and all received the planned radiation dose.
  • One patient out of 3 developed grade III-IV mucositis.
  • At a median follow-up of 31 months, 13.3% of patients had a loco-regional progression and 20% developed distant metastases.
  • Induction chemotherapy followed by alternating chemo-radiotherapy is feasible and patients' compliance optimal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Prospective Studies. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Cancer Research CampaignCopyright 2000 Cancer Research Campaign.
  • [Cites] Cancer. 1976 Jun;37(6):2605-12 [820419.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2270-83 [9840526.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Apr;7(4):447-53 [6788731.001]
  • [Cites] Natl Cancer Inst Monogr. 1982;62:47-55 [7167194.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Dec;10(12):2241-9 [6511521.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Aug;11(8):1455-9 [3926733.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1789-93 [2412999.001]
  • [Cites] Cancer. 1986 Jun 15;57(12):2267-71 [3084058.001]
  • [Cites] Chin Med J (Engl). 1987 May;100(5):419-24 [3115715.001]
  • [Cites] Cancer. 1988 Mar 15;61(6):1117-24 [3342372.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1401-10 [3047335.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):311-4 [2921131.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Aug;5(4):821-38 [1890068.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):261-70 [1587745.001]
  • [Cites] N Engl J Med. 1992 Oct 15;327(16):1115-21 [1302472.001]
  • [Cites] Ann Oncol. 1994 Feb;5(2):159-62 [8186159.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):569-77 [7558945.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):985-96 [9169804.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Apr;6(4):401-7 [7390921.001]
  • (PMID = 11076650.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2363421
  •  go-up   go-down


Advertisement
4. Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, Lo YM: Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer; 2003 Jul 15;98(2):288-91
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
  • BACKGROUND: Patients with International Union Against Cancer (UICC) Stage I-II nasopharyngeal carcinoma (NPC) appear to have a relatively favorable prognosis and generally are excluded from trials of combined modality treatment.
  • More recently, plasma/serum cell-free Epstein-Barr virus (EBV) DNA has been shown to be measurable in the majority of NPC patients at the time of diagnosis, and appears to have prognostic significance.
  • This issue has management implications because different therapeutic strategies currently are employed for patients with good-risk and those with poor-risk NPC.
  • METHODS: A cohort of 90 patients with UICC Stage I-II NPC (World Health Organization Grade 2/3 histology) had their pretherapy plasma/serum EBV DNA levels determined by a quantitative polymerase chain reaction assay and correlated with the probability of posttherapy failure.
  • All patients received radiation therapy only, except for three patients who also received concurrent chemotherapy.
  • RESULTS: With a median follow-up time of 45 months, 12 patients and 7 patients, respectively, had developed locoregional and distant failures, including 2 patients with both local and distant failures.
  • CONCLUSIONS: Within a group of patients with UICC Stage I-II NPC, the pretherapy plasma EBV DNA level was found to identify a poor-risk group with a probability of distant failure similar to that of patients with advanced stage disease.
  • The prognostic significance of designating Stage IIB disease as per the 1997 UICC staging was confirmed, although the pretherapy EBV DNA level appears to be a more powerful prognostic discriminator in patients with early-stage NPC.
  • [MeSH-major] DNA, Viral / blood. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / isolation & purification. Nasopharyngeal Neoplasms / blood. Nasopharyngeal Neoplasms / virology
  • [MeSH-minor] Humans. Neoplasm Metastasis. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12872347.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


5. Righini ChA, Soriano E, Morel N, Hitter A, Bolla M, Reyt E: [Combined induction chemotherapy and radiotherapy in case of undifferentiated carcinoma of nasopharynx tumours (UCNT)]. Rev Laryngol Otol Rhinol (Bord); 2006;127(4):223-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined induction chemotherapy and radiotherapy in case of undifferentiated carcinoma of nasopharynx tumours (UCNT)].
  • [Transliterated title] Traitement par chimiothérapie d'induction et radiothérapie des cancers du cavum de type UCNT.
  • OBJECTIVE: The objectives of our study were to consider the morbidity and the effectiveness of combined induction chemotherapy and radiotherapy in the treatment of Undifferentiated Carcinoma of Nasopharynx Tumor (UCNT).
  • PATIENTS AND METHODS: It was a retrospective study (1987-2002) of patients who had not received any previous treatment.
  • Two types of chemotherapy were administered: The BAC regime (Bleomycin, Adriamycin, Cisplatinum) and the FUCIFOL regime (Fluorouracil, Cispaltinum, Elvorin).
  • On the whole, the tolerance of the treatment was good (chemotherapy 71%, radiotherapy 82%).
  • Treatment mortality was null.
  • At the end of the treatment, a total response was obtained in 82% of cases.
  • The commonest cause of treatment failure was the emergence of metastases (64% of deaths).
  • With multivariate analysis, the independent variables inductive radiotherapy and the initial response to treatment were significantly linked to death with a respective p value of 0.02 and 0.0084.
  • CONCLUSIONS: Combined induction chemotherapy and radiotherapy is efficient in the treatment of UCNT.
  • The tolerance of treatment was good.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315786.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Ho JC, Lam DC, Wong MK, Lam B, Ip MS, Lam WK: Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung. J Thorac Oncol; 2009 Sep;4(9):1174-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung.
  • Lymphoepithelioma-like carcinoma (LELC) of lung has previously demonstrated good clinical response to 5-fluorouracil containing chemotherapy regimen, similar to the observation in undifferentiated nasopharyngeal carcinoma.
  • Capecitabine, which is converted into active 5-fluorouracil within tumor cells, has been found effective in colorectal, breast, and recently nasopharyngeal carcinomas.
  • We report our experience in five patients with advanced or metastatic LELC of lung who were treated with single agent capecitabine as salvage chemotherapy.
  • Future studies on capecitabine-containing chemotherapy regimens in LELC of lung are warranted.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Capecitabine. Disease Progression. Female. Humans. Male. Middle Aged. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19704339.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Kong L, Zhang YW, Hu CS, Guo Y: Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma. Chin J Cancer; 2010 May;29(5):551-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
  • BACKGROUND AND OBJECTIVE: Concurrent chemoradiation therapy (CCRT) is the standard treatment for patients with locally advanced nasopharyngeal carcinoma (NPC).
  • The effect of neoadjuvant chemotherapy followed by CCRT has not been determined.
  • Therefore, we conducted 2 phase II studies to evaluate the efficacy and safety of neoadjuvant chemotherapy with a regimen of docetaxel, cisplatin, and 5 fluorouracil (5-Fu) (TPF) followed by radiotherapy and concurrent cisplatin in patients with stage III and IV(A - B) NPC.
  • This article is the preliminary report on treatment related toxicities and response.
  • METHODS: Graded according to the 2002 American Joint Committee on Cancer (AJCC) staging criteria, only patients with stage III or IV(A-B) poorly differentiated or undifferentiated NPC (World Health Organization type II/III) were included.
  • All patients received neoadjuvant chemotherapy with TPF (docetaxel 75 mg/m(2), day 1; cisplatin 75 mg/m(2), day 1; 5 Fu 500 mg/(m2 x day), continuous intravenous infusion for 120 h), every 3 weeks for 3 cycles, followed by weekly cisplatin (40 mg/m(2)) concurrent with radiotherapy.
  • Gross disease planning target volume (PTV), high risk and low risk subclinical PTV doses were prescribed at 70-76 Gy, 66-70 Gy, and 60-61.25 Gy at 1.75-2.0 Gy per fraction.
  • The lower neck or supraclavicular fields may be treated with conventional AP/PA fields for a total of 54 Gy at 1.8 Gy per fraction.
  • Patients were evaluated for tumor response after the completion of neoadjuvant chemotherapy, and at 3 months after radiation according to the Response Evaluation Criteria In Solid Tumors (RECIST).
  • RESULTS: Fifty nine patients were evaluable for treatment response.
  • All patients completed RT to the prescribed dose and 2 cycles of neoadjuvant chemotherapy, with 51 patients (86.4%) completing 3 cycles.
  • The overall response rate in the primary site and the neck region were 94.9% [complete response (CR) in 25.4%] and 100% (CR in 19.6%) after completing neoadjuvant chemotherapy.
  • After a median follow up of 14.3 months, we observed 5 treatment failures and 2 deaths.
  • The rates of grade 3/4 myelosuppression and anorexia/nausea/vomiting during neoadjuvant chemotherapy were 55.9% and 16.9%, respectively.
  • There were no treatment related deaths.
  • CONCLUSIONS: Neoadjuvant chemotherapy with TPF followed by CCRT was well tolerated with a manageable toxicity profile.
  • [MeSH-major] Chemoradiotherapy. Chemotherapy, Adjuvant. Nasopharyngeal Neoplasms / therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Anemia / etiology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / adverse effects. Cisplatin / therapeutic use. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leukopenia / chemically induced. Leukopenia / etiology. Male. Middle Aged. Nausea / chemically induced. Nausea / etiology. Neoplasm Staging. Neutropenia / chemically induced. Neutropenia / etiology. Radiotherapy, Conformal. Radiotherapy, Intensity-Modulated. Remission Induction. Survival Rate. Taxoids / adverse effects. Taxoids / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426907.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Taxoids; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; TPF protocol
  •  go-up   go-down


8. Nakamura RA, Novaes PE, Antoneli CB, Fogaroli RC, Pellizzon AC, Ferrigno R, Maia MA, Salvajoli JV, Pereira AJ, Nishimoto IN: High-dose-rate brachytherapy as part of a multidisciplinary treatment of nasopharyngeal lymphoepithelioma in childhood. Cancer; 2005 Aug 1;104(3):525-31
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose-rate brachytherapy as part of a multidisciplinary treatment of nasopharyngeal lymphoepithelioma in childhood.
  • BACKGROUND: Nasopharyngeal carcinoma in childhood is rare.
  • Radiochemotherapy is considered the standard treatment and yields increased survival and local control rates.
  • In this article, the authors report on the results from the multidisciplinary treatment of pediatric patients who had nasopharyngeal lymphoepithelioma with radiochemotherapy, including high-dose-rate brachytherapy of the primary tumor site.
  • METHODS: Between May 1992 and May 2000, 16 children with nasopharyngeal lymphoepithelioma received neoadjuvant chemotherapy, conventional external beam radiotherapy, high-dose-rate brachytherapy, and adjuvant chemotherapy.
  • Three cycles of neoadjuvant and adjuvant chemotherapy in 3-week intervals were administered with cyclophosphamide, vincristine, doxorubicin, and cisplatin.
  • The median doses of external beam radiotherapy to the primary tumor, positive lymph nodes, and subclinical areas of disease were 55 grays (Gy), 55 Gy, and 45 Gy, respectively.
  • Children received 2 insertions of high-dose-rate brachytherapy at 5 Gy per insertion: These were performed with metallic applicators inserted through the transnasal access under local anesthesia.
  • At the time of last follow-up, 13 patients were alive without disease, 2 patients had died of disease, and 1 patient had died of treatment-related cardiac failure.
  • Chemotherapy-related and radiotherapy-related acute toxicity was relevant but tolerable.
  • CONCLUSIONS: In the current study, it was shown that the treatment was effective in the control of both local and distant disease, although there was relevant acute and late toxicity.
  • Close follow-up of these patients was necessary to evaluate the significance of treatment-related late effects and their impact on quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Child. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15986481.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Lee S, Park SY, Hong EK, Ro JY: Lymphoepithelioma-like carcinoma of the ovary: a case report and review of the literature. Arch Pathol Lab Med; 2007 Nov;131(11):1715-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the ovary: a case report and review of the literature.
  • Lymphoepithelioma-like carcinoma is an undifferentiated carcinoma morphologically characterized by sheets of pleomorphic epithelioid cells with an intense lymphoid infiltrate.
  • Based on a clinical diagnosis of right ovarian carcinoma with lymph node metastases, she received 9 cycles of chemotherapy, resulting in a reduction of her ovarian tumor, disappearance of the enlarged pelvic and para-aortic lymph nodes, and normalization of serum CA 125 level.
  • The histology of the multinodular tumor resembled that of lymphoepithelioma of the nasopharynx and was observed in the right ovary.
  • Lymphoepithelioma-like carcinoma appears to be rare in the female genital tract.
  • [MeSH-major] Carcinoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. CA-125 Antigen / blood. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979492.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen
  • [Number-of-references] 16
  •  go-up   go-down


10. Ho JC, Wong MP, Lam WK: Lymphoepithelioma-like carcinoma of the lung. Respirology; 2006 Sep;11(5):539-45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the lung.
  • Lymphoepithelioma-like carcinoma (LELC) of the lung was first reported in 1987.
  • This uncommon but distinct form of non-small cell lung carcinoma has a predilection for young non-smoking Asians, without gender distinction.
  • Histologically, it is indistinguishable from undifferentiated nasopharyngeal carcinoma.
  • In order to establish the diagnosis of LELC of the lung, both nasopharyngeal carcinoma and lymphoma have to be excluded by endoscopic biopsy (with or without magnetic resonance imaging of the nasopharynx) and immunohistochemical staining of the biopsy samples.
  • The mainstay of treatment for early-stage disease is curative surgical resection, whereas multimodality treatment (surgery, chemotherapy, radiotherapy) has been adopted in advanced or metastatic diseases.
  • The overall survival is more favourable in LELC of the lung compared with non-LELC type of non-small cell lung carcinoma.
  • Future collaborative studies especially on optimizing treatment for this uncommon malignancy are clearly warranted.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung / pathology. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916325.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 40
  •  go-up   go-down


11. Kochbati L, Boussen H, Gritli S, Besbes M, Benna F, Saadi A, el May A, Ben Ayed F, Ladgham A, Maalej M: [Secondary mandibular fibrosarcoma after chemoradiotherapy for undifferentiated nasopharyngeal carcinoma. Report of a case and review of the literature]. Cancer Radiother; 2001 Jun;5(3):283-6
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Secondary mandibular fibrosarcoma after chemoradiotherapy for undifferentiated nasopharyngeal carcinoma. Report of a case and review of the literature].
  • [Transliterated title] Fibrosarcome secondaire de la mandibule après chimioradiothérapie pour carcinome indifférencié du nasopharynx. A propos d'une observation et revue de la littérature.
  • Secondary tumours to radio- and/or chemotherapy have rarely been reported after treatment for head and neck cancers.
  • We report a case of mandibular fibrosarcoma observed 7 years after chemoradiotherapy for undifferentiated nasopharyngeal carcinoma in a patient treated when 20 years old.
  • [MeSH-major] Carcinoma / radiotherapy. Fibrosarcoma / etiology. Mandibular Neoplasms / etiology. Nasopharyngeal Neoplasms / radiotherapy. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11446083.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 23
  •  go-up   go-down


12. Chen M, Lin S, Zheng W: [Therapeutic effect of medical therapy upon undifferentiated nasopharyngeal carcinoma: analysis of 149 cases]. Zhonghua Yi Xue Za Zhi; 2001 Dec 25;81(24):1488-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic effect of medical therapy upon undifferentiated nasopharyngeal carcinoma: analysis of 149 cases].
  • OBJECTIVE: To study the therapeutic effect and prognosis of undifferentiated nasopharyngeal carcinoma.
  • METHODS: 149 patients with undifferentiated nasopharyngeal carcinoma, 4 at stage I, 33 at stage II, 73 at stage III, and 39 at stage IV according to the Fuzhou Staging Criteria of Nasopharyngeal Carcinoma 1992, were treated mainly by radiotherapy from 1999 to 2000: 78 of them underwent radiotherapy alone, 32 underwent radiotherapy combined with induced chemotherapy, and 39 underwent radiotherapy combined with synchronized chemotherapy.
  • Relevant clinical data, especially the therapeutic effect upon and prognosis of the type, were analyzed.
  • RESULTS: Undifferentaited nasopharyngeal carcinoma accounts for 3.58% of nasopharyngeal carcinoma and was with a 5-year overall survival rate (OS) of 64.48%, a disease-free survival rate (DFS) of 60.35%, a distance-metastasis-free (DMF) survival rate of 77.05%, and a local recurrence free (LRF) survival rate of 80.13%.
  • CONCLUSION: Undifferentiated nasopharyngeal carcinoma is a rare type.
  • Treatment maninly on radiotherapy is effective.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200771.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Boussen H, Kochbati L, Oueslati Z, Gritli S, Daoud J, Gammoudi A, Besbes M, Bouaouina N, Benna F, Ladgham A, Maalej M: [Metachronous cancers after treatment for undifferentiated nasopharyngeal carcinoma]. Ann Otolaryngol Chir Cervicofac; 2004 Nov;121(5):282-5
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metachronous cancers after treatment for undifferentiated nasopharyngeal carcinoma].
  • [Transliterated title] Cancers métachrones après traitement des carcinomes indifférenciés du cavum.
  • OBJECTIVE: To collect second cancers occurring in the head and neck area after treatment by chemotherapy and/or radiotherapy for undifferentiated nasopharyngeal carcinoma in Tunisia.
  • PATIENTS AND METHODS: This is a retrospective study of patients developing second cancers after treatment for nasopharyngeal UCNT by radiotherapy and/or chemotherapy.
  • Patients have been treated for nasopharyngeal UCNT mainly advanced T3-T4 (72%) or N2-N3 (63%).
  • Treatment protocol included primary chemotherapy in 4 cases (adriamycin-cisplatin) or adjuvant (in 4) associated to the loco-regional irradiation at a mean dose of 72 Gy (70 to 75).
  • Tumors were epidermoid carcinomas in 4 cases, fibrosarcomas (2), osteosarcomas (2), glioblastoma (1) and basocellular carcinomas in 2.
  • Second tumors have been treated by surgery alone in 4 cases and chemotherapy alone in 7 patients.
  • CONCLUSION: Even very rare, second cancers after treatment for UCNT need to be detected and have a poor prognosis.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / therapy. Fibrosarcoma / pathology. Fibrosarcoma / therapy. Glioblastoma / pathology. Glioblastoma / therapy. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / therapy. Neoplasms, Second Primary / pathology. Osteosarcoma / pathology. Osteosarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711481.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


14. Wong ZW, Tan EH, Yap SP, Tan T, Leong SS, Fong KW, Wee J: Chemotherapy with or without radiotherapy in patients with locoregionally recurrent nasopharyngeal carcinoma. Head Neck; 2002 Jun;24(6):549-54
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with or without radiotherapy in patients with locoregionally recurrent nasopharyngeal carcinoma.
  • BACKGROUND: Treatment of locoregionally recurrent nasopharyngeal carcinoma (NPC) is challenging because of prior radiotherapy, morbidities from disease recurrence, and limited therapeutic options available.
  • METHODS: A retrospective study of patients with locoregionally recurrent NPC.
  • RESULT: Between March 1994 and December 1999, there were 42 patients; most were Chinese (98%) men (81%) with undifferentiated NPC (86%).
  • The remaining 22 (group 2) received palliative chemotherapy (PF) with a response rate of 50%.
  • Six (14%) developed systemic metastases at 12 months (median) from first recurrence.
  • CONCLUSION: Concurrent chemoradiotherapy for locoregional recurrent NPC seems promising.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Fluorouracil / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Male. Middle Aged. Palliative Care. Radiotherapy Dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc.
  • (PMID = 12112552.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Poon D, Chowbay B, Leong SS, Cheung YB, Toh CK, Tay MH, Lim WT, Tan EH: Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC). J Clin Oncol; 2004 Jul 15;22(14_suppl):5576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC).
  • : 5576 Background: Advanced NPC is chemosensitive and responsive even to third-line salvage regimen, therefore the continued search for active agents to enhance salvage potential.
  • Topoisomerase I targeters have been shown to induce apoptosis in NPC cell lines in in-vitro experiments.
  • This phase II study was designed to evaluate efficacy and safety of irinotecan in patients with advanced NPC.
  • METHODS: Eligibility criteria included AJCC stage IVC nasopharyngeal undifferentiated carcinoma, ECOG performance status (PS) 0-2, progressive disease during or less than 3 months after platinum-based and/or taxane-based regimen, and bidimensionally measurable disease.
  • Irinotecan at 100 mg/m<sup>2</sup> was administered on days 1, 8, 15, every 28 days up to maximum of 6 cycles, or until disease progression or appearance of non-tolerable toxicity.
  • Patient characteristics included mean age 50.9 (standard deviation - SD 7.5), 21 males; 4 females, 23 (92%) are Chinese, 22 (88%) had ECOG PS 0-1, and a mean 2.0 (SD 1.8) prior lines of chemotherapy.
  • CONCLUSIONS: Preliminary results from this trial suggest that irinotecan is an active agent as salvage treatment with modest toxicity in patients with advanced NPC refractory to platinum/taxane-based chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014014.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Djedi H, Bouzid K: Capecitabine-based chemotherapy versus primary treatment for patients with advanced stages of undifferentiated nasopharyngeal carcinoma (UCNT): Preliminary results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e17049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine-based chemotherapy versus primary treatment for patients with advanced stages of undifferentiated nasopharyngeal carcinoma (UCNT): Preliminary results of a phase II study.
  • : e17049 Background: The combination of cisplatin and 5-fluorouracil (5-FU) is considered to be the standard treatment in induction chemotherapy for patients with undifferentiated nasopharyngeal carcinoma (UCNT).
  • The aim of our study is to evaluate overall response and toxicity of this drug as a primary chemotherapy based-regimen for patients with advanced stages of UCNT.
  • All patients received at least 3 to 4 courses of neoadjuvant chemotherapy.
  • The treatment plan included cisplatin at dose of 75 mg/m2 on D1 every 21 days, followed by capecitabine at a dose of 1,000 mg/m2 twice daily from D2 to D 15, with a 1-week rest period.
  • A CT scan was done at the end of treatment before radiotherapy.
  • RESULTS: After a total of 114 courses, all patients (34 pts) were evaluable for toxicity and 26 patients were evaluable for response (8 pts have not yet achieved their treatment).
  • A clinical benefit was obtained for all patients since the first cure of chemotherapy.
  • Chemotherapy was interrupted for one patient after only one cure because of the cardiac toxicity.
  • CONCLUSIONS: Capecitabine based chemotherapy is a safety and an effective regimen in patients with UCNT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961741.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kerboua E: Capecitabine and cisplatyl as neoadjuvant treatment of locally advanced nasopharyngeal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e17036

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine and cisplatyl as neoadjuvant treatment of locally advanced nasopharyngeal carcinoma.
  • : e17036 Background: The main objective of this study is to evaluate the activity and safety of capecitabine (X) and cisplatyl (C) in patients (pts) with locally advanced nasopharyngeal carcinoma(NPC).
  • Capecitabine was reported to have single-agent activity in advanced/metastatic NPC.
  • METHODS: Pts with undifferentiated NPC type were enrolled from July 2007 to September 2008.
  • They received X 1,000 mg/m<sup>2</sup>orally bid on days 1-14 + C 75/m<sup>2</sup> IV day 1 q 3W, Three cycles were administered in a neoadjuvant setting before radiotherapy.
  • RESULTS: Forty-one (41) pts have been enrolled 28 male/13 female with locally advanced NPC: 15 pts (36,6% ) were stage III (UICC 1997) 26 pts (63,3%) stage IV (n = 6 IVA and n = 20 IVB).
  • Two pts died from sepsis that was probably treatment-related.
  • CONCLUSIONS: Preliminary results show that X plus C provide an active regimen with an acceptable tolerability profile as neoadjuvant chemotherapy for locally advanced NPC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961801.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Beldjilali Y, Benhadji KA, Boukerche A, Khellafi H, Abdelaoui A, Betkaoui F, Tourabi ZK, Kaïd MY, Djellali L, Yamouni M: First results of induction chemotherapy with cisplatin, docetaxel, and capecitabine for the treatment of nasopharyngeal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):6045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First results of induction chemotherapy with cisplatin, docetaxel, and capecitabine for the treatment of nasopharyngeal carcinoma.
  • : 6045 Background: The purpose of this phase II study is to assess a new induction chemotherapy regimen combining cisplatin (P), docetaxel (T), and capecitabine (X) in advanced nasopharyngeal carcinoma.
  • METHODS: Previously untreated patients (pts) with histological diagnosed locally advanced nasopharyngeal carcinoma (stages III, IVA, and IVB UICC 2002) received induction chemotherapy associating P 75 mg/m<sup>2</sup>, T 75 mg/m<sup>2</sup>, both on day 1 and X 1,000 mg/m<sup>2</sup>/d days 1-14.
  • Induction chemotherapy was followed by concurrent chemo-radiotherapy: P 75 mg/m<sup>2</sup> days 1, 22, 42 and radiotherapy (65-70 Gy) 4 to 6 weeks after the fourth cycle of induction treatment.
  • Pts were evaluated according to RECIST criteria by clinical examination and CT scan of the nasopharynx.
  • 30 pts (75%) had an undifferentiated carcinoma of nasopharyngeal type (UCNT) and 10 pts (25%) a poorly differentiated nasopharyngeal carcinoma.
  • CONCLUSIONS: PTX induction chemotherapy resulted on a high response rate with manageable toxicity.
  • Outcome of patients after chemoradiotherapy is awaited to evaluate the effectiveness of this new treatment modality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961921.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yamouni M, Benhadji KA, Beldjilali Y, Lahfa I, Khellafi H, Abdelaoui A, Djellali L, Bouzid K: Phase II trial of combination docetaxel and cisplatin in patients with locally advanced nasopharyngeal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):6044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of combination docetaxel and cisplatin in patients with locally advanced nasopharyngeal carcinoma.
  • : 6044 Background: The standard treatment of locally advanced nasopharyngeal carcinoma is cisplatin-based chemotherapy followed by locoregional radiotherapy.
  • The purpose of this study is to assess the antitumor activity and toxicity of a new neoadjuvant chemotherapy regimen combining docetaxel (D) and cisplatin (C).
  • METHODS: Previously untreated patients (pts) with histologically diagnosed locally advanced nasopharyngeal carcinoma (stages IVA and IVB, TNM/UICC 1997) received D 75 mg/m<sup>2</sup> and C 75 mg/m<sup>2</sup> both on day 1, with cycles repeated every 21 days.
  • All pts received three cycles in a neoadjuvant setting before radiotherapy (4 to 6 weeks after the third cycle of DC, 65-70 Gy 5 fractions/week).
  • Pts were evaluated by clinical examination, CT scan of the nasopharynx, and nasofibroscopy with biopsy.
  • 75 pts (81%) had an undifferentiated carcinoma of nasopharyngeal type (UCNT) and 18 pts (19%) a differenciated carcinoma of the nasopharynx.
  • CONCLUSIONS: DC chemotherapy followed by radiation therapy is an effective regimen for the treatment of advanced UCNT and has an acceptable safety profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961920.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Toh CK, Heng D, Ong YK, Leong SS, Fong KW, Tan T, Wee J, Tan EH: A new prognostic index score for metastatic nasopharyngeal carcinoma: A validation study. J Clin Oncol; 2004 Jul 15;22(14_suppl):5575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new prognostic index score for metastatic nasopharyngeal carcinoma: A validation study.
  • : 5575 Background: Patients with metastatic undifferentiated nasopharyngeal carcinoma (mets NPC) comprise a heterogeneous group with varying survival duration.
  • METHODS: The present cohort included 137 mets NPC pts.
  • Eighty-eight percent of them received chemotherapy and this proportion is higher than that in our previous cohort.
  • We re-analyzed the previous cohort to include only pts who received chemotherapy to derive a new PIS (nPIS) that stratified the pts into 3 prognostic groups with significantly different median survivals.
  • The nPIS was applied to the present cohort of 118 pts who was treated with chemotherapy.
  • RESULTS: The significant prognostic variables in the nPIS included poor performance status of ECOG ≥2, short disease-free interval (DFI) of < 6 mths, presence of mets at initial diagnosis, and anemia of Hb<12 g/dl.
  • A score of 0 was assigned if the factor was absent or 1 for mets at initial diagnosis, 4 for anaemia, 5 for ECOG≥2 and 10 for short DFI.
  • Fifty-seven pts were good prognosis, 43 intermediate prognosis and 18 poor prognosis, with median survival of 20.2 (95% CI 15.2, 25.2), 14.3 (95% CI 12.3, 16.2) and 7.9 (95% CI 6.6, 9.2) months respectively. (logrank test: p=0.003) Conclusions: The nPIS is validated in our present cohort of mets NPC pts who received chemotherapy.
  • The factors involved are readily available in the clinics and will prove useful as a method for risk assessment and stratification of pts with mets NPC.
  • With stratification also come uniform classification and consistent reporting in clinical trials that will help us better interpret results of any therapeutic intervention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014016.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Suzuki S, Ishikawa K: Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer. J Infect Chemother; 2009 Oct;15(5):335-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
  • S-1 is an oral 5-fluorouracil (5-FU) anticancer agent and has shown promising effects in the treatment of a wide range of carcinomas, including head and neck cancer.
  • In addition to being used as adjuvant chemotherapy, S-1 is a promising agent for palliative treatment.
  • Its ease of administration makes it an ideal drug to treat patients in the outpatient setting while maintaining adequate quality of life.
  • However, the clinical role of S-1 in patients with recurrent/metastatic head and neck cancer is still uncertain.
  • Thirteen patients with squamous cell carcinoma (SCC) and 3 patients with non-SCC who had recurrent/metastatic disease received S-1 monotherapy as outpatients.
  • One patient with nasopharyngeal undifferentiated carcinoma and 1 patient with maxillary adenosquamous carcinoma showed complete response (CR), while all SCC patients showed stable disease (SD) or progressive disease (PD).
  • Median time to progression (TTP) was 12 weeks.
  • Except for one episode of grade 4 leucopenia which required hospitalization and granulocyte colony-stimulating factor (GCSF) treatment, all adverse events resolved with dose reduction or dose omission.
  • S-1 was safely administered in outpatients and showed some efficacy in the treatment of recurrent/metastatic head and neck cancer in patients who had received previous chemotherapy.
  • S-1 could be used as palliative treatment in patients with recurrent/metastatic head and neck cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Palliative Care. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged. Drug Combinations. Female. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856075.001).
  • [ISSN] 1437-7780
  • [Journal-full-title] Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • [ISO-abbreviation] J. Infect. Chemother.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


22. Chua DT, Sham JS, Choy D, Kwong DL, Au GK, Kwong PW, Yau CC, Cheng AC, Wan KY: Patterns of failure after induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma: the Queen Mary Hospital experience. Int J Radiat Oncol Biol Phys; 2001 Apr 1;49(5):1219-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma: the Queen Mary Hospital experience.
  • PURPOSE: Our center contributed 183 patients to the Asian-Oceanian Clinical Oncology Association (AOCOA) multicenter randomized trial comparing induction chemotherapy (CT) followed by radiotherapy (RT) vs. RT alone in patients with locoregionally advanced undifferentiated nasopharyngeal carcinoma (NPC).
  • In a preliminary report no difference in terms of overall survival or relapse-free survival was found between the 2 treatment arms.
  • To study the long-term outcome and patterns of failure after CT for NPC, we analyzed our own center data for which a uniform radiation treatment protocol was adopted and a longer follow-up time was available.
  • Patients with newly diagnosed NPC of Ho's T3 disease, N2-N3 disease, or with neck node size of at least 3 cm were eligible.
  • Stratification was made according to the nodal size (< or = 3 cm, >3- 6 cm, > 6 cm).
  • Four patients were excluded from the current analysis (2 died before treatment, 2 received treatment elsewhere).
  • The remaining 179 patients were randomized to the two treatment arms, with 92 to the CT arm and 87 to the RT arm.
  • Two patients in the CT arm had RT only, and all patients completed radiation treatment.
  • At the time of analysis, 50% of patients in the CT arm and 61% in the RT arm had relapse, while 32% in the CT arm and 36% in the RT arm had died of the disease.
  • CONCLUSION: Induction chemotherapy with the regimen used in the current study did not improve the treatment outcome or alter the failure patterns in patients with locoregionally advanced NPC, although there was a trend suggesting better nodal control in the combined modality arm.
  • Alternative strategies of combining chemotherapy and radiotherapy should be tested and employed instead.
  • [MeSH-major] Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Remission Induction. Survival Analysis. Treatment Failure

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11286826.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Ponzanelli A, Vigo V, Marcenaro M, Bacigalupo A, Gatteschi B, Ravetti JL, Corvò R, Benasso M: Induction chemotherapy followed by alternating chemo-radiotherapy in non-endemic undifferentiated carcinoma of the nasopharynx: optimal compliance and promising 4-year results. Oral Oncol; 2008 Aug;44(8):767-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy followed by alternating chemo-radiotherapy in non-endemic undifferentiated carcinoma of the nasopharynx: optimal compliance and promising 4-year results.
  • Concomitant chemo-radiotherapy is the standard treatment for advanced nasopharyngeal carcinoma (NPC).
  • Induction chemotherapy may improve the results further by enhancing both loco-regional and distant control.
  • Fifty patients with untreated, stage IV (UICC 1992) undifferentiated NPC were initially treated with three courses of epidoxorubicin, 90 mg/m(2), day 1 and cisplatin, 40 mg/m(2), days 1 and 2, every three weeks and then underwent three courses of cisplatin, 20 mg/m(2)/day, days 1-4 and fluorouracil, 200mg/m(2)/day, days 1-4 (weeks 1, 4, 7), alternated to three splits of radiation (week 2-3, 5-6, 8-9-10) up to 70 Gy.
  • All patients but one received 3 cycles of induction chemotherapy.
  • Toxicities from induction chemotherapy were grade III or IV mucositis (2%), grade III or IV nausea/vomiting (22%), grade III or IV hematological toxicity (6%).
  • In locally advanced UNPC our combined program including induction chemotherapy followed by alternating chemo-radiotherapy is active and gives promising long-term outcomes with acceptable toxicity and optimal patients' compliance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma, Squamous Cell / drug therapy. Nasopharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Epidemiologic Methods. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / metabolism. Treatment Outcome. Young Adult

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061519.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, Eschwege F, Armand JP, Simon J, Cvitkovic E: Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol; 2000 Mar;18(6):1324-30
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type.
  • PURPOSE: To review incidence and analyze profile of long-term complete responders among patients with undifferentiated carcinoma of nasopharyngeal type (UCNT) treated at a single institution.
  • PATIENTS AND METHODS: We present a cohort of 20 long-term unmaintained complete responders to chemotherapy for metastatic UCNT treated at the Institut Gustave Roussy between April 1978 and November 1996.
  • A patient was considered a long-term survivor if he or she was disease-free for more than 36 months without treatment after obtaining a complete response by chemotherapy.
  • Of 16 pretreated patients, 11 were pretreated by radiotherapy alone and five by chemotherapy and radiotherapy.
  • Chemotherapy included the following: cisplatin, bleomycin, and fluorouracil in five patients; bleomycin, epirubicin, and cisplatin in seven patients; fluorouracil, mitomycin, epirubicin, and cisplatin in four patients; and fluorouracil, bleomycin, epirubicin, and cisplatin in one patient.
  • RESULTS: As of June 1999, 14 of 20 patients were still alive with no evidence of disease after treatment (disease-free survival time, 82+ to 190+ months), three patients died of other causes while in complete response at 61, 109, and 208 months after treatment, and three patients died of disease at 42, 89, and 115 months after treatment.
  • CONCLUSION: Our data support a curative role for chemotherapy in metastatic UCNT and are a major incentive to continue research for better combinations to increase the percentage of patients with metastatic UCNT who attain complete responses and long-term survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Nasopharyngeal Neoplasms / drug therapy. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10715304.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Chua DT, Kwong DL, Sham JS, Au GK, Choy D: A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer; 2000 Apr;36(6):736-41
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy.
  • The aim of this study was to evaluate the efficacy and toxicity of ifosfamide, 5-fluorouracil (5-FU) and leucovorin (IFL) as a second-line chemotherapy regimen in patients with recurrent undifferentiated nasopharyngeal carcinoma (NPC) previously treated with platinum/5-FU.
  • All patients had previously received platinum/5-FU as adjuvant or palliative treatments.
  • The median time to progression for all patients was 6.5 months (95% CI: 4.2-8.7).
  • Treatments were well tolerated, only 1 patient had grade 3 emesis.
  • IFL is an effective second-line regimen in patients with recurrent NPC and is well tolerated with mild toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / drug therapy. Platinum Compounds / administration & dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10762745.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Platinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


26. Akman F, Sen M, Erdag T, Cetinayak O, Eyiler F: Accelerated radiotherapy in locally advanced head-neck carcinomas: are concomitant boost and chemotherapy feasible in the routine outpatient-based radiotherapy clinic? J BUON; 2002 Jul-Sep;7(3):221-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated radiotherapy in locally advanced head-neck carcinomas: are concomitant boost and chemotherapy feasible in the routine outpatient-based radiotherapy clinic?
  • PURPOSE: Accelerated radiotherapy and concurrent chemoradiotherapy is an effective treatment modality in locally advanced head and neck carcinomas.
  • In this study, we examined the efficacy and feasibility of concomitant boost radiotherapy and chemotherapy in the routine outpatient- based radiotherapy clinic.
  • PATIENTS AND METHODS: Between January 1993 and December 2000, only 51 out of 127 eligible patients were deemed suitable to receive concomitant boost radiotherapy and/or chemotherapy.
  • The histological diagnosis was squamous-cell carcinoma in 38 (75%) patients, undifferentiated nasopharyngeal carcinomas (WHO type III) in 10 (20%) patients and other histology in 3 (5%) patients.
  • The concomitant boost regimen consisted of 70 Gy in 6 weeks (1.8 Gy/fraction/day, 5 days/week, to the clinical target volume (CTV), and 1.6 Gy/fraction/day to the gross tumor volume (GTV) as a second-daily treatment for the last 2 weeks).
  • The concomitant chemotherapy regimen consisted of cisplatin 100 mg/m(2) given every 3 weeks for 3 courses, and the neoadjuvant regimen of cisplatin 100 mg/m(2) plus epirubicin 100mg/m(2), every 3 weeks for 3 courses.
  • RESULTS: Only 55% of patients completed the treatment exactly as planned, with 82% completing treatment within acceptable limits.
  • In univariate analysis, patients with better performance status (p=0.002) or nasopharyngeal carcinomas (p=0.043) had a significantly better compliance to treatment.
  • In multivariate analysis only nasopharyngeal site was a significant predictor of compliance (p=0.019).
  • Patients with nasopharyngeal cancer and good treatment compliance had a better response rate (p=0.009 and 0.01, respectively).
  • CONCLUSION: In the routine outpatient-based setting we found that this intensive treatment schedule can only be given to a limited and highly selected group of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17918792.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


27. Shet T, Arora B, Laskar S, Basak R, Kane S, Kurkure P: Epstein-barr virus-associated lymphoepithelioma-like carcinoma of mandible. Pediatr Dev Pathol; 2009 Mar-Apr;12(2):152-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-barr virus-associated lymphoepithelioma-like carcinoma of mandible.
  • We describe the first case of an lymphoepithelioma-like carcinoma (LEC) of the mandible with a view to discuss probable histogenesis from salivary gland inclusions in the mandible, effective therapy, the unusual pattern of nodal metastases, and association with the Epstein-Barr virus.
  • The mandibular tumor on biopsy showed morphology similar to an undifferentiated carcinoma or LEC of nasopharynx with nuclear Epstein-Barr virus-associated in situ hybridization signals.
  • The patient received ifosfamide, cisplatin, and etoposide chemotherapy followed by a hemimandibulectomy, which did not reveal any residual tumor.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / isolation & purification. Mandibular Neoplasms / virology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Disease-Free Survival. Humans. Lymph Nodes / pathology. Lymph Nodes / virology. Male. Mandible / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457481.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Nasr Ben Ammar C, Chaari N, Kochbati L, Attia I, Ben Hamadi D, Chebbi A, Saadi A, Besbes M, Maalej M: [Brain radionecrosis in patients irradiated for nasopharyngeal carcinoma: about nine cases]. Cancer Radiother; 2007 Sep;11(5):234-40
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain radionecrosis in patients irradiated for nasopharyngeal carcinoma: about nine cases].
  • [Transliterated title] Radionécrose cérébrale chez les patients irradiés pour cancer du nasopharynx: à propos de neuf cas.
  • PURPOSE: To study the clinical, radiological, therapeutic and progressive aspects of brain radionecrosis after treatment for nasopharyngeal carcinoma.
  • PATIENTS AND METHODS: Nine patients (seven men and two women) of mean age 47.7 years old (extremes: 18-57 years old) were treated for UCNT (undifferentiated carcinoma of the nasopharynx) between 1989 and 2003 and developed cerebral radionecrosis.
  • The mean total dose was 73.5 Gy (70-75 Gy).
  • Dose per fraction was 2 to 2.5 Gy, one fraction daily.
  • One patient received adjuvant brachytherapy to the dose of 8 Gy and four patients also received chemotherapy.
  • The time to the appearance of neurological signs was 40.3 months (10 to 108 months).
  • After a mean follow-up period of 30.6 months (12-84 months), clinical outcomes were favorable in all cases receiving medical treatment (corticoids), with a stabilization of the radiological lesions in eight cases and complete radiological regression in one patient.
  • Imaging techniques (CT scan but more so MRI) play a major role in the diagnosis.
  • [MeSH-major] Brain / pathology. Nasopharyngeal Neoplasms / radiotherapy. Radiation Injuries / pathology. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Adult. Age Factors. Analgesics / therapeutic use. Blood-Brain Barrier. Brachytherapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nasopharynx / pathology. Necrosis. Neoplasm Staging. Radiotherapy Dosage. Remission Induction. Risk Factors. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631405.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Analgesics
  •  go-up   go-down


29. Barroso A, Nogueira R, Lencastre H, Seada J, Parente B: Primary lymphoepithelioma-like carcinoma of the lung. Lung Cancer; 2000 Apr;28(1):69-74
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoepithelioma-like carcinoma of the lung.
  • Lymphoepithelioma is an undifferentiated carcinoma with prominent lymphoid stroma in the nasopharynx.
  • Tumors with similar histology have been reported with other localizations, including the lungs, and are designated as lymphoepithelioma-like carcinomas (LELC).
  • This paper details the case of a 25-year-old Caucasian male patient with the diagnosis (determined by thoracotomy) of primary LELC of the lung.
  • Observation of the nasopharynx and a magnetic resonance image of the cavum were normal.
  • Because the tumor (T4N2M0) could not be resected, the patient was treated with chemotherapy, carboplatin/5-fluorouracil, completing two cycles.
  • The patient's condition worsened when he developed contralateral pneumonia, which was then followed by pericardial effusion.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Diagnosis, Differential. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10704712.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Guerrero A, Laflamme M, Agoff SN, Williams WM, Karmy-Jones R: Primary lymphoepithelioma-like carcinoma of the lung. Can Respir J; 2001 Nov-Dec;8(6):431-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoepithelioma-like carcinoma of the lung.
  • Primary lymphoepithelioma-like carcinoma (LELC) of the lung is a neoplasm seen most commonly in the nasopharynx of individuals from south China and Taiwan, and is strongly associated with the Epstein-Barr virus.
  • After it was determined that the neoplasm was of primary lung origin, adjunctive chemotherapy was initiated.
  • The role of adjunctive chemotherapy in this setting is discussed.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Granuloma, Respiratory Tract / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11753457.001).
  • [ISSN] 1198-2241
  • [Journal-full-title] Canadian respiratory journal
  • [ISO-abbreviation] Can. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


31. Chang YL, Wu CT, Shih JY, Lee YC: New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am J Surg Pathol; 2002 Jun;26(6):715-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas.
  • Lymphoepithelioma-like carcinoma, an uncommon epithelial tumor, has been described as being closely associated with Epstein-Barr virus (EBV) infection in many organs, especially the nasopharynx.
  • We experienced 23 cases of lymphoepithelioma-like carcinoma arising in the lung from 2498 lung cancer patients in the Cancer Registry of our hospital.
  • All tumors showed the typical syncytial growth pattern of undifferentiated epithelial cells with a significant CD8+ T-lymphocyte reaction.
  • EBV viral capsid antigen IgG level remained elevated despite response to therapy.
  • Nearly all cases had bcl-2 oncoprotein expression, but the detection rate of latent membrane protein-1, p53, and c-erb B-2 expression was extremely low.
  • The encouraging chemotherapy response for advanced stage disease is also discussed.
  • [MeSH-major] Capsid Proteins. Carcinoma / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12023575.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Capsid Proteins; 0 / Epstein-Barr viral capsid antigen; 0 / Epstein-Barr virus encoded RNA 1; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Viral; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


32. Satyanarayana S, Pathak SD, Saraswat V, Sarma YS, Bharadwaj R, Goorha YK: Tracheal lymphoepithelioma-like carcinoma: a case report. Indian J Cancer; 2002 Jul-Sep;39(3):112-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tracheal lymphoepithelioma-like carcinoma: a case report.
  • Lymphoepithelioma like carcinoma is rare in locations other than nasopharynx.
  • We report the second case of this tumour in trachea, in a young female patient, who was managed with concomitent surgery, radiotherapy and chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Tracheal Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12928566.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


33. Airoldi M, Pedani F, Marchionatti S, Gabriele AM, Succo G, Gabriele P, Bumma C: Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori; 2002 Jul-Aug;88(4):273-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma.
  • BACKGROUND: Recurrent undifferentiated nasopharyngeal carcinoma is a chemosensitive disease.
  • Few third-line treatments have been reported.
  • METHODS: Twelve patients (9 males, 3 females; median age 50 years, range, 20-62) with recurrent undifferentiated nasopharyngeal carcinoma were treated with carboplatin AUC 5.5 + paclitaxel (175 mg/m2, 3-hr infusion) on day 1 every 3 weeks.
  • All patients had been previously treated for recurrent disease with a first-line cisplatin-based chemotherapy and a second-line therapy with low-dose continuous infusion 5-fluorouracil.
  • The median survival time was 14 months for patients who had a partial or minimal response or no change, and 5 months for nonresponders.
  • The treatment was well tolerated, and toxicity was manageable.
  • CONCLUSIONS: The combination has a good palliative role as third-line chemotherapy in recurrent undifferentiated nasopharyngeal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12400975.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


34. Brun JL, Randriambelomanana J, Cherier L, Lafon ME, Trufflandier N, Le Bail B: Lymphoepithelioma-like carcinoma of the ovary: a case report and review of the literature. Int J Gynecol Pathol; 2010 Sep;29(5):427-31
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the ovary: a case report and review of the literature.
  • Lymphoepithelioma-like carcinoma (LELC), which is commonly reported in the nasopharynx and occasionally in other organs, remains a rare condition in gynecology.
  • It is morphologically defined as a poorly differentiated carcinoma with prominent lymphoplasmacytic infiltrate.
  • The tumor was a mixed poorly undifferentiated ovarian carcinoma consisting of 95% LELC and 5% moderately differentiated serous adenocarcinoma.
  • Immunohistochemistry showed a large infiltration of T lymphocytes and plasma cells.
  • To our knowledge, this is the second case of ovarian LELC and the first description of the native tumor before chemotherapy.
  • However, clinicians and pathologists should be aware that ovarian tumors with massive involvement of lymph nodes and no peritoneal carcinomatosis are suggestive of such a diagnosis and that prognosis is relatively good.
  • [MeSH-major] Carcinoma / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736767.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


35. Boussen H, Bouaouina N, Daldoul O, Benna F, Gritli S, Ladgham A: [Update on medical therapies of nasopharyngeal carcinomas]. Bull Cancer; 2010 Apr;97(4):417-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Update on medical therapies of nasopharyngeal carcinomas].
  • [Transliterated title] Actualités des traitements médicaux des cancers du nasopharynx.
  • Nasopharyngeal carcinomas (NPC) are predominantly of undifferentiated type (UCNT or undifferentiated carcinoma of nasopharyngeal type), rare (<1/100,000) and sporadic in occidental countries, but endemic in the Mediterranean area of intermediate incidence (2 to 10/100,000) and highly frequent (>10/100,000) in South East Asia.
  • NPC staging is based on TNM UICC 2002 that has a prognostic and therapeutic orientation impact.
  • Irradiation of the primitive tumor and its extensions remains the standard loco-regional treatment.
  • The recent introduction of primary and concomitant chemotherapy leads to an improvement in terms of overall and disease-free survival, specially for for high-risk-patients (T3-4 and N2-3 disease).
  • Prognosis remain linked to T, N, histologic type and quality of response to chemotherapy and radiotherapy.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Age of Onset. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Dose Fractionation. Humans. Infant. Infant, Newborn. Lymphatic Metastasis. Neoplasm Staging. Treatment Outcome. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20385516.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


36. Gabriele AM, Airoldi M, Beatrice F, Trotti AB: Combined chemo-radiotherapy for stage IV undifferentiated nasopharyngeal carcinoma. Tumori; 2000 Sep-Oct;86(5):399-402
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemo-radiotherapy for stage IV undifferentiated nasopharyngeal carcinoma.
  • Undifferentiated nasopharyngeal carcinoma is a chemosensitive lesion, but its role in the management of local advanced disease is under investigation.
  • Twenty-seven untreated stage IV undifferentiated nasopharyngeal carcinoma patients were treated with radiotherapy (median dose, 66.6 Gy, 1.8 Gy/day) and concomitant cisplatin (100 mg/m2 days 1, 22 and 43).
  • After radiotherapy, we observed 74% complete responses and 26% partial responses; after adjuvant chemotherapy 96% had a complete and 4% a partial response.
  • Concomitant chemotherapy plus radiotherapy was well tolerated, whereas adjuvant chemotherapy was more toxic.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Cisplatin / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Survival Analysis. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11130569.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


37. Ho CL, Lee SH, Chen LM, Chao TY: Epstein-Barr virus early ribonucleic acids as a diagnostic adjunct for relapsed metastatic tumors in patients with cured primary undifferentiated nasopharyngeal carcinoma. Am J Otolaryngol; 2000 Mar-Apr;21(2):80-4
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus early ribonucleic acids as a diagnostic adjunct for relapsed metastatic tumors in patients with cured primary undifferentiated nasopharyngeal carcinoma.
  • PURPOSE: Epstein-Barr virus (EBV) has been consistently shown to be associated with undifferentiated nasopharyngeal carcinoma (NPC).
  • In this article, the authors attempt to detect Epstein-Barr virus in distant relapsed metastatic sites in undifferentiated NPC patients with cured primary cancer.
  • MATERIALS AND METHODS: In situ hybridization (ISH) technique is a reliable method to detect EBV early RNAs (EBERs) within NPC cells.
  • We used a nonisotopical ISH technique to examine the presence of EBERs in paraffin-embedded tissues obtained from 1 paired specimen of primary NPC and its metastatic counterpart at liver and 2 metastatic specimens of retroperitoneal lymph nodes and bone.
  • RESULTS: All the primary lesions and the metastatic tumors of NPC with undifferentiated histology contained EBERs that could be clearly detected in the nuclei of cancer cells.
  • These results suggest that this nonisotopical ISH method of EBERs can be potentially used to diagnose NPC patients developing distant relapsed metastatic lesions with cured primary cancer early.
  • It can offer quick information as to institute suitable salvage chemotherapy for these patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Carcinoma / secondary. Herpesvirus 4, Human / isolation & purification. Nasopharyngeal Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / virology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Bone Neoplasms / virology. Female. Humans. In Situ Hybridization. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Liver Neoplasms / virology. Lymphatic Metastasis. Male. RNA, Viral / analysis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10758991.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral
  •  go-up   go-down


38. Rahimi S, Lena A, Vittori G: Endometrial lymphoepitheliomalike carcinoma: absence of Epstein-Barr virus genomes. Int J Gynecol Cancer; 2007 Mar-Apr;17(2):532-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial lymphoepitheliomalike carcinoma: absence of Epstein-Barr virus genomes.
  • The aim of this study was to report a case of primary lymphoepitheliomalike endometrial carcinoma (FIGO stage IB).
  • A 57-year-old woman presented with an endometrial tumor showing the classic clinical and hysteroscopic aspects of endometrial carcinoma.
  • Morphologically, the neoplasm was similar to undifferentiated nasopharyngeal carcinoma (lymphoepithelioma).
  • We report the third case of an endometrial lymphoepitheliomalike carcinoma (LELC).
  • The patient did not receive chemotherapy and is alive and free of disease 24 month after diagnosis.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / virology. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / virology. Herpesvirus 4, Human / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17362326.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


39. Chow TL, Chow TK, Lui YH, Sze WM, Yuen NW, Kwok SP: Lymphoepithelioma-like carcinoma of oral cavity: report of three cases and literature review. Int J Oral Maxillofac Surg; 2002 Apr;31(2):212-8
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of oral cavity: report of three cases and literature review.
  • Lymphoepithelioma-like carcinoma is a rare tumour in the oral cavity and is characterized histologically by non-keratinizing, undifferentiated squamous cell carcinoma with lymphocytic infiltration.
  • Three consecutive cases of intraoral lymphoepithelioma-like carcinoma are reported.
  • A review of the literature reveals a similar biological behaviour to that of nasopharyngeal lymphoepithelioma: a high incidence of cervical nodal spread and remarkable radiosensitivity.
  • Chemotherapy should be considered when nodal or distant metastases are present.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12102423.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 32
  •  go-up   go-down


40. Bareggi C, Palazzi M, Locati LD, Cerrotta A, Licitral L: Clozapine and full-dose concomitant chemoradiation therapy in a schizophrenic patient with nasopharyngeal cancer. Tumori; 2002 Jan-Feb;88(1):59-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clozapine and full-dose concomitant chemoradiation therapy in a schizophrenic patient with nasopharyngeal cancer.
  • Clozapine is a neuroleptic drug used in selected schizophrenic patients.
  • The potentially dangerous interaction between cancer treatment and clozapine is virtually unknown.
  • A 37-year-old schizophrenic patient under treatment with clozapine, diagnosed with undifferentiated nasopharyngeal carcinoma, was treated with full-dose cisplatin and concomitant radiotherapy without reporting significant neutropenia.
  • Clozapine may be cautiously administered when full-dose concomitant chemoradiation therapy is required.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antipsychotic Agents / therapeutic use. Cisplatin / therapeutic use. Clozapine / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Schizophrenia / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Dose Fractionation. Humans. Male. Neutropenia / chemically induced. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CLOZAPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12004852.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antipsychotic Agents; J60AR2IKIC / Clozapine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


41. Breda E, Catarino R, Azevedo I, Fernandes T, Barreira da Costa C, Medeiros R: [Characterization of the clinical evolution of nasopharyngeal carcinoma in Portuguese population]. Acta Otorrinolaringol Esp; 2007 May;58(5):191-7
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characterization of the clinical evolution of nasopharyngeal carcinoma in Portuguese population].
  • [Transliterated title] Caracterización de la evolución clínica del carcinoma de la nasofaringe en una población portuguesa.
  • OBJECTIVE: Characterization of the clinical evolution of nasopharyngeal cancer (NPC) patients in a Portuguese population during 31 years of follow-up.
  • MATERIALS AND METHOD: Three hundred and twenty patients with epidermoid nasopharyngeal carcinoma were selected for this study.
  • Histological subtypes were analyzed along with survival rates after different treatment schemes and according to AJCC and UICC staging classification systems.
  • RESULTS: The most frequent histological subtype was undifferentiated nasopharyngeal carcinoma.
  • Better survival rates were found in patients treated with adjuvant chemotherapy (cisplatin and 5-fluorouracil) and these findings were similar to other published results.
  • CONCLUSIONS: Although adjuvant chemotherapy may reduce the likelihood of distant metastasis, the latter is still the main cause of death in our study.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498470.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  •  go-up   go-down


42. Toumi N, Frikha M, Siala W, Khabir A, Karray H, Boudawara T, Gargouri RM, Ghorbel M, Daoud J: [Juvenile nasopharyngeal carcinoma: anatomoclinic, biologic, therapeutic and evolutive aspects]. Bull Cancer; 2010 Apr;97(4):427-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Juvenile nasopharyngeal carcinoma: anatomoclinic, biologic, therapeutic and evolutive aspects].
  • [Transliterated title] Les cancers du cavum juvéniles: aspects anatomocliniques, biologiques, thérapeutiques et évolutifs.
  • Nasopharyngeal carcinoma (NPC) represents one of the most frequent epithelial tumours of the child in intermediate risk regions.
  • Its role in the pathogeneses of NPC has been confirmed by several studies.
  • Young NPCs are characterized by a low rate of EBV antibodies and a high level of LMP1 cell expression than in adult's NPC.
  • The undifferentiated carcinoma nasopharyngeal type (UCNT) represents the most frequent histological type.
  • Immunohistochemical analyses of North Africa early onset NPC is characterized by a weak expression of bcl-2 and p53 and a strong expression of LMP1 and c-kit what makes them different from the adult's NPC.
  • Juvenile NPC is characterized by a very important locoregional extension as well as a high rate of distant metastases.
  • More than 15% of patients had metastases at diagnosis.
  • Radiotherapy is still the standard therapy of NPC.
  • Only some retrospectives studies have been published to determine the benefit, the type and the timing of the chemotherapy in the treatment of juvenile NPC.
  • An improvement of the prognosis can be waited with concomitant chemotherapy and intensity modulated radiotherapy.
  • However, randomized multi institutional studies are necessary to standardize the treatment of the NPC in childhood.
  • [MeSH-major] Nasopharyngeal Neoplasms
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant / methods. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human. Humans. Neoplasm Proteins / metabolism. Radiotherapy / methods. Viral Matrix Proteins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20385520.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Neoplasm Proteins; 0 / Viral Matrix Proteins
  •  go-up   go-down


43. Badri T, Zeglaoui F, Kochbati L, Kooli H, El Fekih N, Fazaa B, Kamoun MR: [Multiple basal cell carcinomas following radiation therapy for nasopharyngeal cancer]. Presse Med; 2006 Jan;35(1 Pt 1):55-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple basal cell carcinomas following radiation therapy for nasopharyngeal cancer].
  • [Transliterated title] Carcinomes basocellulaires multiples après radiothérapie pour cancer du cavum.
  • INTRODUCTION: Basal cell carcinoma (BCC) is a cutaneous, generally primary malignancy, most common among the elderly.
  • We report the case of a patient presenting numerous BCCs several years after radiation therapy for nasopharyngeal cancer and discuss the risk factors for this tumor and the role played by radiation in its genesis.
  • Eleven years earlier, she had had an undifferentiated nasopharyngeal carcinoma (T3N2M0), which was treated by neoadjuvant chemotherapy and then external radiation therapy.
  • We found no reports in the literature of BCC following radiation treatment for nasopharyngeal cancer, but the occurrence of these tumors in our patient suggests the need for close supervision in such cases.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Nasopharyngeal Neoplasms / radiotherapy. Neoplasms, Multiple Primary / etiology. Neoplasms, Radiation-Induced / etiology. Radiotherapy / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Nasopharynx / pathology. Neoplasm Staging. Radiotherapy Dosage. Skin / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462665.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


44. Onat H, Basaran M, Esassolak M, Bavbek SE, Anacak Y, Kaytan E, Altun M, Haydaroglu A: High-dose epirubicin and cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol); 2002 Dec;14(6):449-54
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose epirubicin and cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma.
  • AIM: Undifferentiated nasopharyngeal carcinoma (UNPC) is a chemosensitive tumour; a randomized study evaluating neoadjuvant chemotherapy with bleomycin/epidoxorubicin/cisplatin (BEC) in addition to conventional radiotherapy has resulted in a better disease-free survival in the chemotherapy arm.
  • METHODS: Seventy-one patients with locally advanced UNPC were treated with three cycles of C 100 mg/m2 day 1, and EPI 100 mg/m2 day 1 every 3 weeks followed by conventional radiotherapy of 70 Gy.
  • RESULTS: Neoadjuvant chemotherapy was well tolerated.
  • Grade III-IV neutropenia occurred in 18.9% of the cycles: none of the patients developed neutropenic fever.
  • No patient progressed during chemotherapy, the complete response rate was 26.8% (95% CI = 16.9-38.6) and the partial response rate was 59.1% (95% CI = 46.8-70.7) for an objective response rate of 85.9% (95% CI = 75.6-93.0) at the end of the three cycles of chemotherapy.
  • CONCLUSION: Neoadjuvant C and EPI, easily administered in the outpatient setting, is an effective and well-tolerated regimen in the treatment of locally advanced UNPC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Nasopharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12512965.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


45. d'Espiney Amaro C, Montalvão P, Henriques P, Magalhães M, Olias J: Nasopharyngeal carcinoma: our experience. Eur Arch Otorhinolaryngol; 2009 Jun;266(6):833-8
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinoma: our experience.
  • The objectives of our study were to characterize nasopharyngeal carcinoma patients in the Portuguese Institute of Oncology Hospital in Lisbon (IPOLFG) and identify the main factors that interfere with patients survival rate.
  • With an average age of 53 years, most of the carcinomas were type III (58%), followed by type II (30%) and at last type I (8%).
  • Fifty-one of carcinomas were in stage IV at time of diagnosis.
  • There was a significant difference (P = 0.033) in the actuarial survival rate of staged IV patients treated with adjuvant chemotherapy.
  • Undifferentiated nasopharyngeal carcinoma is the most frequent type in our geographic area.
  • Chemotherapy improves survival rate, mainly in late stages.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / therapy. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Portugal / epidemiology. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2007 Apr;117(4):737-42 [17334261.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2627-33 [17473193.001]
  • [Cites] Radiother Oncol. 2003 Dec;69(3):227-36 [14644481.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):582-8 [9690553.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):474-81 [17234754.001]
  • [Cites] Radiother Oncol. 2006 Oct;81(1):39-46 [16965827.001]
  • [Cites] J Clin Virol. 2003 Oct;28(2):155-64 [12957185.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1183-91 [17315158.001]
  • [Cites] J Infect Dis. 2004 Jul 1;190(1):53-62 [15195243.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2002 Mar;111(3 Pt 1):210-6 [11913680.001]
  • [Cites] Head Neck. 1999 Jan;21(1):21-9 [9890347.001]
  • [Cites] Acta Otorrinolaringol Esp. 2007 May;58(5):191-7 [17498470.001]
  • [Cites] Cancer Sci. 2008 Jul;99(7):1311-8 [18498420.001]
  • [Cites] Am J Epidemiol. 2007 Feb 1;165(3):271-8 [17090616.001]
  • [Cites] Laryngoscope. 2007 Jan;117(1):142-6 [17202944.001]
  • [Cites] Head Neck. 2007 Feb;29(2):109-19 [17103409.001]
  • [Cites] Clin Radiol. 2007 Mar;62(3):195-203 [17293211.001]
  • [Cites] J Pathol. 1997 Oct;183(2):164-8 [9390028.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2162-6 [10070282.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):587-93 [8824359.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):622-7 [17149001.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2007 Apr;15(2):99-102 [17413410.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1007-15 [12176778.001]
  • [Cites] BMC Genomics. 2008 Jul 07;9:322 [18605998.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):29-35 [17060483.001]
  • [Cites] Acta Oncol. 2007;46(2):214-20 [17453372.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77 [17035381.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):130-7 [16979842.001]
  • [Cites] J Med Virol. 2006 Aug;78(8):1083-90 [16789009.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):675-9 [9833758.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1287-93 [16909425.001]
  • (PMID = 18830701.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


46. Jiménez-Caballero PE, Marsal-Alonso C, Alvarez-Tejerina A: [Horner syndrome as the first symptom of nasopharyngeal cancer. Two case reports]. Rev Neurol; 2005 May 1-15;40(9):541-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Horner syndrome as the first symptom of nasopharyngeal cancer. Two case reports].
  • [Transliterated title] Sindrome de Horner como primera manifestación del cáncer de cavum. A propósito de dos casos.
  • Nasopharyngeal cancer may damage the cranial nerves, mainly in the cavernous sinus, and very few cases of HS due to infiltration of the tumour into the parapharyngeal space have been reported.
  • The aetiological study revealed a nasopharyngeal lymphoepithelioma; the tumour became smaller and HS disappeared following treatment with chemotherapy.
  • The aetiological study showed a nasopharyngeal lymphoepithelioma and serous otitis.
  • The tumour became smaller and HS disappeared following treatment with chemotherapy.
  • CONCLUSIONS: It is important to carry out studies of the nasopharynx in patients with this syndrome to allow early diagnosis and treatment of a region that is not readily available for direct examination.
  • The existence of an associated pathology in the ear or the paranasal sinuses strongly suggests that its origins lie in the nasopharynx.
  • [MeSH-major] Horner Syndrome / etiology. Nasopharyngeal Neoplasms
  • [MeSH-minor] Aged. Carcinoma / complications. Carcinoma / diagnosis. Carcinoma / pathology. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15898015.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


47. Poon D, Chowbay B, Cheung YB, Leong SS, Tan EH: Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer; 2005 Feb 1;103(3):576-81
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
  • BACKGROUND: This Phase II study was designed to evaluate the efficacy and safety of irinotecan in patients with advanced nasopharyngeal carcinoma (NPC).
  • METHODS: Patients with disseminated, undifferentiated NPC that progressed during or within 3 months of platinum-based and/or taxane-based regimen were eligible.
  • Patient characteristics were as follows: The median age was 46.5 years (range, 40.3-71.6 years), the median number of prior lines of chemotherapy was 2 (range, 1-9), the majority of patients (89%) had good Eastern Cooperative Oncology Group performance status (0-1), and the majority of patients (82.1%) had >/= 2 sites of distant metastases.
  • Global quality-of-life scores were stable during treatment.
  • CONCLUSIONS: Results from this trial suggest that irinotecan is an active salvage agent with modest toxicity in patients with advanced NPC who are refractory to platinum/taxane-based chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Carcinoma / drug therapy. Nasopharyngeal Neoplasms / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Diarrhea / chemically induced. Disease Progression. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Quality of Life. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society
  • (PMID = 15612023.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


48. Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, Mok TS, Kam M, Chan LS, Chiu SK, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PM, Zee B: Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol; 2004 Aug 1;22(15):3053-60
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.
  • PURPOSE: To assess the efficacy of neoadjuvant paclitaxel and carboplatin (TC) followed by concurrent cisplatin and radiotherapy (RT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and to monitor treatment response with plasma Epstein-Barr virus (EBV) DNA.
  • PATIENTS AND METHODS: Thirty-one patients with International Union Against Cancer stages III and IV undifferentiated NPC had two cycles of paclitaxel (70 mg/m2 on days 1, 8, and 15) and carboplatin (area under the curve 6 mg/mL/min on day 1) on a 3-weekly cycle, followed by 6 to 8 weeks of cisplatin (40 mg/m2 weekly) and RT at 66 Gy in 2-Gy fractions.
  • Plasma EBV DNA was measured serially using the real-time quantitative polymerase chain reaction method.
  • Results All patients completed planned treatment.
  • Response to neoadjuvant TC was as follows: 12 patients (39%) achieved partial response (PR) and 18 achieved (58%) complete response (CR) in regional nodes; five patients (16%) achieved PR and no patients achieved CR in nasopharynx.
  • At 6 weeks after RT, one patient (3%) achieved PR and 30 patients (97%) achieved CR in regional nodes, and 31 patients (100%) achieved CR in nasopharynx; 29 patients (93%) had EBV DNA level of less than 500 copies/mL.
  • Plasma EBV DNA level increased significantly in eight of nine patients who experienced treatment failure but did not increase in those who did not.
  • Serial plasma EBV DNA provides a noninvasive method of monitoring response in NPC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Cisplatin / administration & dosage. DNA, Viral / blood. Herpesvirus 4, Human / isolation & purification. Nasopharyngeal Neoplasms / therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Drug Administration Schedule. Environmental Monitoring / methods. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Survival Rate

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Society of Clinical Onocology
  • (PMID = 15284255.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Viral; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


49. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, Armand JP: Nasopharyngeal carcinomas: an update. Eur J Cancer; 2003 Oct;39(15):2121-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinomas: an update.
  • Among the group of head and neck cancers, nasopharyngeal carcinomas (NPC) represent a distinct entity in terms of their epidemiology, clinical presentation, biological markers, carcinogenic risk factors, prognostic factors, treatment and outcome.
  • Undifferentiated NPC (UCNT), the most frequent histological type, is endemic in certain regions, especially in South East Asia.
  • Although NPC is a radiosensitive and chemosensitive tumour, a substantial number of patients develop local recurrence or distant metastases.
  • New techniques of radiation and new combined radiotherapy and chemotherapy modalities have been evaluated in numerous clinical trials in recent years.
  • The purpose of this article is to review the current knowledge in terms of the epidemiology, biology, prognosis, management and outcome of patients with NPC.
  • [MeSH-major] Nasopharyngeal Neoplasms
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Epstein-Barr Virus Infections / complications. Female. Humans. Male. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Tumor Virus Infections / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14522369.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 145
  •  go-up   go-down


50. Hsieh WS, Soo R, Peh BK, Loh T, Dong D, Soh D, Wong LS, Green S, Chiao J, Cui CY, Lai YF, Lee SC, Mow B, Soong R, Salto-Tellez M, Goh BC: Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res; 2009 Feb 15;15(4):1435-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer.
  • PURPOSE: Cell cycle dysregulation resulting in expression of antiapoptotic genes and uncontrolled proliferation is a feature of undifferentiated nasopharyngeal carcinoma.
  • The pharmacodynamic effects of seliciclib, a cyclin-dependent kinase (CDK) inhibitor, were studied in patients with nasopharyngeal carcinoma.
  • EXPERIMENTAL DESIGN: Patients with treatment-naïve locally advanced nasopharyngeal carcinoma received seliciclib at 800 mg or 400 mg twice daily on days 1 to 3 and 8 to 12.
  • Paired tumor samples obtained at baseline and on day 13 were assessed by light microscopy, immunohistochemistry, and transcriptional profiling using real-time PCR low-density array consisting of a panel of 380 genes related to cell cycle inhibition, apoptosis, signal transduction, and cell proliferation.
  • CONCLUSIONS: Brief treatment with this regimen of seliciclib in patients with nasopharyngeal carcinoma is tolerable at 400 mg bd and associated with tumor pharmacodynamic changes consistent with cdk inhibition, and warrants further efficacy studies in this tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Cycle / drug effects. Nasopharyngeal Neoplasms / drug therapy. Purines / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Apoptosis / drug effects. Cyclin D1 / analysis. DNA, Viral / blood. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Myeloid Cell Leukemia Sequence 1 Protein. Proto-Oncogene Proteins c-bcl-2 / analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19228744.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CCND1 protein, human; 0 / DNA, Viral; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Purines; 0 / roscovitine; 136601-57-5 / Cyclin D1
  •  go-up   go-down


51. Ayan I, Kaytan E, Ayan N: Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol; 2003 Jan;4(1):13-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood nasopharyngeal carcinoma: from biology to treatment.
  • Nasopharyngeal carcinoma is a rare disease in children with distinct epidemiological, histopathological, and clinical characteristics.
  • Children with nasopharyngeal carcinoma almost always have the undifferentiated variant of the disease, which is associated with advanced locoregional spread and distant metastases.
  • Both genetic and environmental factors contribute to the development of nasopharyngeal carcinoma, as evidenced by its risk factors which include: specific HLA subtypes; deletions of chromosomes 3p, 9p, 11q, 13q, and 14q; mutations of p53 and RB2/p130; polymorphism of the CYP2E1; and infection with Epstein-Barr virus.
  • Traditional treatment consists of high-dose radiotherapy and cure rates range between 30% and 60%.
  • The high incidence of failure due to systemic disease in children means that chemotherapy is preferable for first-line treatment in advanced-stage disease.
  • Currently, cisplatin-based induction or adjuvant chemotherapy combinations are used along with high-dose radiotherapy.
  • Although combined modality treatment has increased 5-year survival to 70-90%, late morbidity is a major concern.
  • [MeSH-major] Carcinoma. Nasopharyngeal Neoplasms

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12517535.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


52. Airoldi M, De Crescenzo A, Pedani F, Marchionatti S, Gabriele AM, Succo G, Rosti G, Bumma C: Feasibility and long-term results of autologous PBSC transplantation in recurrent undifferentiated nasopharyngeal carcinoma. Head Neck; 2001 Sep;23(9):799-803
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and long-term results of autologous PBSC transplantation in recurrent undifferentiated nasopharyngeal carcinoma.
  • BACKGROUND: Recurrent undifferentiated nasopharyngeal carcinoma (UNPC) is a chemosensitive illness.
  • Here we report long-term results of high-dose chemotherapy (HDC) as late intensification, with autologous peripheral blood stem cell (PBSC) support.
  • All patients had been previously treated with neoadjuvant chemotherapy and radiotherapy; 3 of 4 local relapses had received a re-irradiation.
  • RESULTS: After conventional chemotherapy, we had 1 CR (16%), 3 PR (50%), and 2 NC (34%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / therapy. Hematopoietic Stem Cell Transplantation. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / administration & dosage. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Epirubicin / administration & dosage. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / therapy. Transplantation, Autologous

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 John Wiley & Sons, Inc.
  • (PMID = 11505492.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


53. Zubizarreta PA, D'Antonio G, Raslawski E, Gallo G, Preciado MV, Casak SJ, Scopinaro M, Morales G, Sackmann-Muriel F: Nasopharyngeal carcinoma in childhood and adolescence: a single-institution experience with combined therapy. Cancer; 2000 Aug 1;89(3):690-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinoma in childhood and adolescence: a single-institution experience with combined therapy.
  • BACKGROUND: A high cure rate may be attained for locally advanced, undifferentiated nasopharyngeal carcinoma (NPC) in children, provided that a combined modality of treatment is employed.
  • Both local and systemic therapies are necessary.
  • METHODS: From November 1988 to December 1997, 16 consecutive patients were treated with NPC at the Hospital Garrahan in Buenos Aires, Argentina.
  • Chemotherapy consisted of 3 courses, every 3 weeks, of 5-fluorouracil (500 mg/m(2)) plus bleomycin (15 mg/m(2)) daily for 4 days, with cisplatin (100 mg/m(2)) added the last day.
  • External beam radiotherapy was delivered over a median of 52 (range, 45-63) days, to a median cumulative dose to the primary site of 55 (range, 50-61.2) grays (Gy).
  • The median dose for the lower neck area was 45 (range, 45-55.8) Gy.
  • All patients received radiotherapy to the primary site and to the initially involved lymphoid areas, with daily single doses of 1.8 Gy (5 of 7 days per week).
  • Complete response was achieved in 45% of patients after initial chemotherapy.
  • With a median follow-up of 63 (range, 23-119) months, disease free survival (with standard error [SE]) and overall survival estimates were 61% (16%) and 91% (9%), respectively, at 75 months.
  • Acute toxicity due to therapy was tolerable.
  • CONCLUSIONS: Although this series is small, the authors concluded that NPC patients have a good chance of survival in the setting described, in spite of locally advanced disease.
  • Chemotherapy might be useful in preventing the development of systemic metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Nasopharyngeal Neoplasms / therapy. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Child. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Herpesvirus 4, Human / isolation & purification. Humans. Male. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10931470.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


54. Kong L, Lu JJ, Hu C, Guo X, Wu Y, Zhang Y: The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy. Cancer; 2006 Sep 15;107(6):1287-93
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy.
  • However, risk factors for SPTs have not been documented well, especially in nasopharyngeal carcinoma (NPC).
  • The objective of this retrospective analysis was to evaluate such risks in patients with NPC after they received definitive radiation treatment.
  • METHODS: Three hundred twenty-six consecutive patients with pathologically confirmed, nonmetastatic, undifferentiated NPC who received treatment between January 1, 1994 and December 30, 1995 were analyzed.
  • There were 18 patients (5.5%) with Stage I NPC, 152 patients (46.6%) with Stage II NPC, 101 patients (31.0%) with Stage III NPC, and 55 patients (16.9%) with Stage IVA or IVB NPC at initial diagnosis.
  • All patients received definitive radiotherapy with either Cobalt-60 or megavoltage therapy.
  • High-dose-rate brachytherapy was given to 23 patients either as part of their primary treatment or as adjuvant treatment for residual lesions.
  • Seventeen patients (5.2%) developed SPTs, for an average annual rate of 1.0%, and the 5-year cumulative incidence was 5.8%.
  • Multivariate analysis showed that age was the only independent risk factor for developing SPTs after RT for NPC.
  • Other factors, including gender, tumor or lymph node classification, chemotherapy, total radiation dose to the nasopharynx, reirradiation, and adjuvant brachytherapy did not influence the risk of SPTs.
  • CONCLUSIONS: SPTs in patients with NPC occurred preferentially in the UADT and tended to develop within the irradiated field >5 years after patients received radiation.
  • Older patients with NPC (age >or=50 years) may be at increased risk.
  • [MeSH-major] Nasopharyngeal Neoplasms / radiotherapy. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16909425.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Ong YK, Tan HK: Nasopharyngeal carcinoma in children. Int J Pediatr Otorhinolaryngol; 2000 Sep 29;55(2):149-54
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinoma in children.
  • Nasopharyngeal carcinoma (NPC) is rare in children.
  • The various aspects of NPC in children are discussed.
  • Undifferentiated NPC or lymphoepithelioma is the commonest variety.
  • When children present with both conditions simultaneously, it is imperative to manage them like adult patients and perform nasendoscopy to rule out NPC.
  • Radiotherapy with neo-adjuvant chemotherapy is currently the treatment of choice.
  • [MeSH-major] Carcinoma / diagnosis. Nasopharyngeal Neoplasms / diagnosis. Otitis Media with Effusion / diagnosis
  • [MeSH-minor] Anti-Bacterial Agents. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Child. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Radiotherapy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11006455.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


56. Turowski B, Zanella FE: Interventional neuroradiology of the head and neck. Neuroimaging Clin N Am; 2003 Aug;13(3):619-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular interventions are important and helpful for treatment of various pathologies of the head and neck.
  • Interventional neuroradiology of the head and neck includes image-guided biopsies, vessel occlusion, and local chemotherapy.
  • Knowledge of anatomy, functional relationships between intra- and extracranial vessels, and pathology are the basis for therapeutic success.
  • Neuroradiologic imaging, especially CT and MR imaging, and appropriate analysis of angiographic findings help ensure indication for treatment and plan an intervention.
  • Effective treatment of vascular malformations, such as AV fistulas or angiomas, needs exact occlusion of the fistula or the angiomatous nidus, which is demonstrated in the case of an AV angioma of the base of the tongue.
  • Chemotherapy with local intra-arterial cisplatin combined with intravenous administration of sodium thiosulfate as antidote is indicated as an adjuvant modality in a multimodal regimen of oropharyngeal squamous cell carcinoma or as palliative treatment of recurrent and otherwise untreatable malignant tumors of the head and neck.
  • Examples are a carcinoma of the alveolar ridge, a squamous cell carcinoma of the floor of the mouth, and a nasopharyngeal lymphoepithelioma.
  • Palliative treatment of a bleeding oropharyngeal cancer is another example of interventional treatment.
  • Selective treatment, either occluding or pharmacologic, may be preoperative, palliative, or curative.
  • The objective is reduction of surgical risk, improvement of quality of life, or curative therapy of a lesion.
  • Thus, the interventional treatment should not be associated with morbidity or mortality.
  • The benefits, risks, and expected damages of neuroradiologic interventions must be balanced during the informed consent procedure with the patient.
  • [MeSH-major] Head and Neck Neoplasms / radiography. Head and Neck Neoplasms / therapy. Neuroradiography. Radiology, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631695.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


57. Gastaud O, Demailly M, Guilbert E, Colombat M, Petit J: [Lympho-epithelioma of the bladder. Discussion of pathogenesis]. Prog Urol; 2002 Apr;12(2):318-20
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Le carcinome lympho-épithélial de vessie. Discussion pathogénique.
  • Lympoepithelioma, originally described within the nasopharynx is an undifferenciated malignant epithelial tumor with a prominent lymphoid stroma.
  • We report a case of lymphoepithelioma of the bladder after intravesical BCG treatment for carcinoma in situ.
  • [MeSH-major] Carcinoma / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] BCG Vaccine / therapeutic use. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12108352.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


58. Tao Y, Bidault F, Bosq J, Bourhis J: Distant metastasis of undifferentiated carcinoma of nasopharyngeal type. Onkologie; 2008 Nov;31(11):574-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distant metastasis of undifferentiated carcinoma of nasopharyngeal type.
  • [MeSH-major] Anesthetics, Combined / administration & dosage. Carcinoma / secondary. Carcinoma / therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Nasopharyngeal Neoplasms / secondary. Nasopharyngeal Neoplasms / therapy

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Onkologie. 2008 Nov;31(11):635-6 [19145100.001]
  • (PMID = 19145087.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anesthetics, Combined
  •  go-up   go-down






Advertisement